Sustained Release Inner Ear Delivery of Corticosteroid

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$99,550.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43DC008477-01A1
Agency Tracking Number:
DC008477
Solicitation Year:
2007
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
AURITEC PHARMACEUTICALS, INC.
AURITEC PHARMACEUTICALS, INC., 2181 E FOOTHILL BLVD, PASADENA, CA, 91107
Hubzone Owned:
N
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
148679884
Principal Investigator:
WILLIAM SLATTERY
(626) 376-4070
wslattery@hei.org
Business Contact:
THOMAS SMITH
(626) 372-0386
tsmith@auritecpharma.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The long term goal of this research is to reduce or eliminate deafness due to certain diseases of the inner ear by developing sustained release formulations for anti-inflammatory drugs which can be implanted directly into the inner ear. The initial project will be to develop an inner ear delivery system for corticosteroids. The specific aims of this proposal are to: 1, formulate sustained release suspensions of the corticosteroid rimexolone; 2, test the in vitro release characteristics of these formulations into buffer; and 3, test the in vivo pharmacokinetics and the safety of the formulations after implantation into the inner ear of the guinea pig. In previous work, supported in part through SBIR Phase 1 and 2 funding, we have developed the FDA approved intraocular delivery systems Vitrasert(r), and Retisert(r): an implant that delivers therapeutic doses to the inside of the eye for 3 years with a single implantation. The team of investigators is expert in polymer chemistry, pharmacokinetics, drug development, and clinical otology. We have experience in all aspects of the drug development process, from concept to approval and marketing. The successful completion of these specific aims will constitute a readily identifiable milestone which will permit us to continue with Phase 2 of this proposal where we will test the efficacy of the devices in animal models of sensorineural hearing loss and complete the requisite laboratory work to apply for an Investigational New Drug Exemption from the FDA. Many forms of deafness could be treated with drugs; however, most drugs do not penetrate sufficiently into the inner ear and therefore cannot be effective. Because corticosteroids have the potential to treat several diseases, we are developing a sustained release inner ear delivery system for this class of drugs. This system could also be used for other drugs where chronic delivery is essential.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government